Roche: to increase supply of Regeneron's antibody cocktail
(CercleFinance.com) - Roche is collaborating with Regeneron to increase the supply of the US biotech company's antibody cocktail for non-hospitalised Covid-19 patients, the Swiss drugmaker said on Wednesday.
The move comes as the US Department of Health and Human Services (HHS) and the Department of Defense (DoD) have signed an agreement to buy 1.25 million additional doses of Regeneron's antibody cocktail, bringing the total potential US supply to over 1.5 million doses.
Roche said it is working with Regeneron to increase the global supply of casirivimab and imdevimab, aiming to have over 2 million treatment doses available annually.
Under the deal, Regeneron is responsible for the development and distribution of the treatment in the US, and Roche is primarily responsible for the development and distribution outside the US.
Basel-based Roche said it is actively working with governments outside of the US on potential supply agreements.
For context, the combination of casirivimab and imdevimab has been granted US FDA emergency use authorization for recently-diagnosed, high-risk, mild-to-moderate coronavirus patients.
Copyright (c) 2021 CercleFinance.com. All rights reserved.